Dr. Reddy's Laboratories Ltd.

Financial

	Dr. Reddy's Lab	Mankind Pharma	Zydus Lifesciences
Operational Metrics
Pharmaceutical Sector
Number of ANDA's Filed in USA	362.0 .	67.0 .	486.0 .
Number of ANDA's Approved By USFDA	292.0 .	48.0 .	421.0 .
Domestic Sales Growth - YoY	9.1 %	7.9 %	6.7 %
Global DMFs filed	1263.0 .	n/a	n/a
R&D as a % of Total Sales	7.3 %	2.2 %	8.1 %
Financials
5 yr Average ROE	15.68 %	20.33 %	18.47 %
5yr average Equity Multiplier	1.41	1.46	1.52
5yr Average Asset Turnover Ratio	0.74	0.81	0.66
5yr Avg Net Profit Margin	15.18 %	17.68 %	19.02 %
Price to Book	3.03	7.38	3.99
P/E	17.92	55.87	21.1
5yr Avg Cash Conversion Cycle	74.48 Days	-13.08 Days	-84.89 Days
Inventory Days	76.14 Days	59.06 Days	36.38 Days
Days Receivable	95.44 Days	34.35 Days	36.93 Days
Days Payable	102.6 Days	121.69 Days	160.15 Days
5yr Average Interest Coverage Ratio	35.66	46.07	30.19
5yr Avg ROCE	21.82 %	25.06 %	19.65 %
5yr Avg Operating Profit Margin	23.61 %	24.62 %	24.4 %
5 yr average Debt to Equity	0.12	0.16	0.17
5yr CAGR Net Profit	23.71 %	9.49 %	16.23 %
5yr Average Return on Assets	11.24 %	14.46 %	12.22 %
Shareholdings
Promoter Holding	26.64 %	72.68 %	74.99 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-0.07 %	-3.82 %	0.11 %
Change in Mutual Fund Holding (3 Yrs)	-0.6 %	5.51 %	0.94 %

Business

	Dr. Reddy's Lab	Mankind Pharma	Zydus Lifesciences
Product Wise Break-Up	Product Wise Break-Up Formulations 86.8 Pharmaceutical 11.32 Proprietary 1.88 Urology 0 Neuro/CNS 0 Pain/Analgesics 0 Gynaecology 0 Dermatology 0 Anti-Diabetic 0 Respiratory 0 VMN 0 Gastro - Intestinal 0 Cardiovascular 0 Anti-infectives 0 IM Formulations 0 Emerging Markets 0 Europe Formulatios 0 Alliances 0 API 0 Wellness 0 Animal Health 0 India Formulations 0 US Formulations 0	Product Wise Break-Up Neuro/CNS 5.0 Proprietary 0 Dermatology 5.0 Urology 5.0 Pharmaceutical 0 IM Formulations 0 India Formulations 0 Anti-infectives 16.0 Wellness 0 VMN 7.0 Gastrointestinal 11.0 Animal Health 0 Formulations 0 Cardiovascular 13.0 US Formulations 0 Gynaecology 13.0 Respiratory 8.0 Pain/Analgesics 4.0 Europe Formulatios 0 Alliances 0 API 0 Anti-Diabetic 8.0 Emerging Markets 0 Others 5.0	Product Wise Break-Up Neuro/CNS 0 Proprietary 0 Dermatology 0 Urology 0 Pharmaceutical 0 EMB Formulations 8.91 India Formulations 24.75 Anti-infectives 0 Wellness 13.86 VMN 0 Gastro - Intestinal 0 Animal Health 0 Formulations 0 Cardiovascular 0 US Formulations 49.5 Gynaecology 0 Respiratory 0 Pain/Analgesics 0 Europe Formulatios 0 Alliance 0.45 Active Pharmaceutical Ingredient (API) 1.98 Anti-Diabetic 0 Emerging Markets 0 Others 0.55
Location Wise Break-Up	Location Wise Break-Up USA 48.56 India 17.36 Russia 7.99 Nepal 0 Sri Lanka 0 Bangladesh 0 Others 26.09	Location Wise Break-Up Russia 0 India 83.0 USA 0 Sri Lanka 0 Bangladesh 0 Nepal 0 Others 17.0	Location Wise Break-Up Russia 0 India 41.0 USA 44.89 Sri Lanka 0 Bangladesh 0 Nepal 0 Others 14.11
Operating Profit Break-Up	Operating Profit Break-Up Global Generics 94.76 Proprietary Products 3.0 Pharmaceutical Services and Active Ingredients 2.24 Consumer Products 0 Pharmaceuticals 0	-	Operating Profit Break-Up 0 Global Generics 0 Proprietary Products 0 OTC 9.09 Pharmaceuticals 90.91
Therapeutic Area Break-Up	Therapeutic Area Break-Up Oncology 27.53 Central Nervous System (CNS) 12.12 Pain Management 9.77 Gastro Intestinal 9.52 Respiratory 7.04 Cardiac Science 6.65 Anti-Infective 6.48 Dermatology 3.13 Gynaecology 0 Gastro Intestinal 0 Cardiac 0 Others 17.76	-	Therapeutic Area Break-Up Respiratory Systems 13.0 Cardiac Science 16.0 Pain Management 8.0 Anti-Infective 13.0 Oncology 0 Dermatology 6.0 Central Nervous System (CNS) 0 Gastro Intestinal 9.0 Gynecology 6.0 Cardiac Science 0 Others 29.0
Asset Break-Up	Asset Break-Up India 80.24 Switzerland 8.45 USA 2.37 USA 0 Others 8.94	-	Asset Break-Up USA 2.65 India 94.06 Switzerland 0 Others 3.29

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd.

SIGN UP FOR FREE